都道府県・市町村向け 新型インフルエンザ等特措法 …1) 入門編 •感染症とは? •感染源と感染経路 •輸入感染症と人類を脅かす感染症
骨科感染性疾病之治療 成大醫院藥劑部 林妏娟 2009.5.23. 骨科感染性疾病...
-
Upload
paulina-morgan -
Category
Documents
-
view
340 -
download
0
Transcript of 骨科感染性疾病之治療 成大醫院藥劑部 林妏娟 2009.5.23. 骨科感染性疾病...
骨科感染性疾病之治療
成大醫院藥劑部林妏娟
2009.5.23
骨科感染性疾病
Infectious arthritis 感染性關節炎
Osteomyelitis 骨髓炎
Outline
• Pathophysiology
• Microbiology
• Clinical features
• Diagnosis
• Treatment
Acute Bacterial Arthritis
Septic arthritis, pyogenic arthritis Incidence
– 2~10 cases per 100,000 per year– 28~38 cases per 100,000 per year
Morbidity:50% Mortality:10-30%
Pathophysiology
Hematogenously acquired
Direct inoculation of bacteria into the joint through surgery, trauma, percutaneous puncture
Contiguous spread from adjacent infected soft tissue or bone
Predisposing Factors
Joint disease– Rheumatoid arthritis– Crystal-induced arthritis– Osteoarthritis
Chronic systemic disease– DM, chronic renal failure, chronic liver disease, malignancy, sickle
cell disease Immunosuppression
– HIV infection, immunosuppressant therapy, organ and bone marrow transplantation
Trauma– Surgery, penetrating injury, intra-articular injection
Prosthetic joint IV drug use Endocarditis Skin disease or lesions
Microbiology-1 Organism Isolates No.(% of total)
Microbiology-2 Rheumatoid arthritis S. aureus
IV drug use S. aureus, Pseudomonas aeruginosa
Diabetes, malignancy S. aureus, group B streptococci
Immuno-compromised hosts S. aureus, streptococci, enteric Gram-negative bacilli
Neonates, children < 2y/o Gram-negative bacilli, Kingella kingae
Cat or dog bite Pasteurella multocida, Capnocytophaga sp., anaerobes
Human bite Eikenella corrodens, anaerobes, other oral flora
Rat bite Streptobacillus moniliformis
Postpartum women Mycoplasma hominis
Residents or travelers to Southeast Asia
Burkholderia pseudomallei
Microbiology-3
GNB– 5-20%– Neonates, elderly, IV drug users, immunoco
mpromised hosts– Escherichia coli– Pseudomonas aeruginosa– Kingella kingae
Cultures of synovial fluid or blood:10-20% Polymicrobial flora:8%
Clinical Features
Monarticular– Knee, shoulder, wrist, ankle; hips; small joints of
the foot & hand Polyarticular
– RA, immunosuppression, bacteremia Symptoms
– Pain, loss of function, swelling, redness, increased warmth of the infected joint, fever, malaise
– ESR, CRP– Purulent, low-viscosity synovial fluid, PMN– Culture: synovial fluid, blood– Gram stain
Diagnosis
Definitive etiologic diagnosis Blood, wound, skin lesions Synovial fluid examination CT or MRI Acute attacks of the crystalline joint
disease, gout; preexist-rheumatoid or other inflammatory arthritis
Treatment
Antibiotics, joint drainage, joint rest joint drainage
– Needle aspiration (hip?)– Arthroscopy– Open surgical drainage
Antimicrobial therapy should be delayed until arthrocentesis and cultures are obtained
Initial antimicrobial therapy– Synovial fluid Gram staining– Likely infecting pathogens
Definitive treatment– Cultures
Recommended Empirical Therapy for Adult Native Joint Bacterial Arthritis
Gram Stain Antimicrobial
GPC
No risk factors for MRSA
Oxacillin 2 g q4h
Cefazolin 2g q8h
Clinidamycin 900mg q8h
Vancomycin 1g q12h
Risk factors for MRSA Vancomycin 1g q12h
GNC Ceftriaxone 1g q24h
GNR Ceftazidime or cefepime 2g q8h
Piperacillin-tazobactam 4.5g q6h
Imipenem 500mg q6h
Meropenem 1g q8h
Azetreonam 2g q8h
Ciprofloxacin 400mg q12h
Levofloxacin 750mg qd
Recommended Empirical Therapy for Adult Native Joint Bacterial Arthritis
Gram Stain Antimicrobial
Gram stain negative Regimen for gram-positive cocci above plus
Ceftazidime
Ciprofloxacin
Levofloxacin)
Aminoglycoside
Tobramycin
Gentamicin 5-7mg/kg once
daily or 5mg/kg in three
divided doses per day
MRSA
IV vancomycin Linezolid and daptomycin may be an opti
on for patients with joint infection with MRSA who are allergic to, intolerant of, or not clinically responding after 3-5 days of vancomycin
※Risk factors: recent inpatient, nursing home resident, leg ulcers or catheters..
Gonococcal arthritis
Ceftriaxone, cefotaxime, ceftizoxime Oral ciprofloxacin or levofloxacin Therapy can be switched on the fourth d
ay to oral amoxicillin or to doxycycline or tetracycline
Special Populations
< I month– Broad-spectrum– Oxacillin + AG
<5 years– H. influenzae– Nafcillin, oxacillin, cefazolin
>5 y/o and adults– S. aureus– Penicillinase resistant penicillin, clindamycin, vancomycin, li
nezolid IV drug abuses
– P. aeruginosa– Combination of AG
Antimicrobial therapy
Septic arthritis related to animal or human bites– Aerobic and anaerobic oral flora– Ampicillin-sulbactam, amoxicillin-clavulanat
e, clindamycin+ciprofloxacin The penetration of inflamed joints is ade
quate for most intravenous and some oral antimicrobials.
Duration
2-4 weeks S. aureus, including MRSA, gram-negati
ve bacilli Gram-negative septic arthritis in which t
he organism is susceptible to FQ Gonococcal arthritis
Monitor
Culture and sensitivity WBC CRP ESR Clinical signs of inflammation
Fungal Arthritis
Fungal Arthritis
Healthy hosts– Direct trauma or injury, penetrating foreign b
ody– Blastomyces dermatitidis, Coccidioides spp.,
Paracoccidioides brasiliensis, Sporothrix schenckii
Immunocompromised hosts– Penetrating injury or hematogenous spread – Candida spp., Cryptococcus, Aspergillus
Fungal Arthritis-Candida Arthritis
Risk factors– Loss of skin integrity– Diabetes– Malignancy– Malnutrition– Premature birth– IV drugs use– Immunosuppressive therapy– Prolonged use of broad-spectrum A/B– Central intravenous catheters
Fungal Arthritis-Candida Arthritis
Candida albicans Candida tropicalis, Candida parapsilosis,Can
dida guilliermondii, Candida glabrata Knee Fever Synovial fluid: polymorphonuclear leukocytosi
s, low measured glucose Gram stain, cultures… Blood cultures: <50%
Treatment
Combined medical and surgical modalities Amphotericin B with or without flucytosine Native joint Candida arthritis:
– Amphotericin B 0.5-1mg/kg/day for 2-3 weeks followed by fluconazole to complete a total duration of therapy of 6-12 months
– Fluconazole 6 mg/kg/day for 6-12 months– Caspofungin may be an option for Candida spp. isol
ates that are resistant to azole drugs in patients who are intolerant of amphotericin B
Treatment Cryptococcal arthritis
– Amphotericin B followed by oral fluconazole
Coccidioides, Blastomyces, Histoplasma, Sporothrix– Isolated joint infection without CNS involve
ment– itraconazole 200-400mg/day for 12 months
Voriconazle– Aspergillus
Mycobacterial Arthritis
Mycobacterial Arthritis
All TB: 1-3% Extra-pulmonary TB: 10-11% Risk factors
– Lower socioeconomic class, alcohol abuse, debilitating illness, IV drug use, immunosuppressive drug therapy, HIV infection, preexisting joint disease
~J Microbiol Immunol Infect 2007;40:493-499
~J Microbiol Immunol Infect 2007;40:493-499
Mycobacterial Arthritis
Mycobacterium tuberculosis Knee, hip, ankle Fever and other symptoms Tuberculin skin testing Synovial fluid:
– leukocytes counts 10000-20000 cells/mm3– Staining (acid-fast bacilli)– Culture (80%)– Synovial biopsy
Mycobacterial Arthritis
CDC recommendation– Skeletal TB in adults without pulmonary TB– Isoniazid, rifampin, ethambutol, and pyrazi
namide – 8 weeks– Followed by isonizid and rifampin to compl
ete 6 months of therapy Adjuvant surgical therapy
Prosthetic joint infection
Prosthetic joint infection
Early– First 3 months– Surgical procedure
Delay– 3 months ~2 years– Surgical procedure
Late– >2 years– Hematogenous spread
Staphylococcus aureus Staphylococcus epidermidis Genitourinary and Gastrointestinal tract
procedures infections (Gram negative rods, Enterococci and anaerobes)
Dental infection (viridans streptococci, Peptococcus spp. and Peptostreptococcus spp.)
Skin infections (Streptococcus spp.)
Prosthetic joint infection
Biofilms
S. aureus and coagulase-negative staphylococci (CoNS)
10–1000 times bacteriain in biofilms are surrounded by
an extracellular matrix
~NEJM 2004;351:1645-54
Prosthetic joint infection
Diagnosis: sum Antimicrobial therapy
– no standards (agents, ideal regimen, duration )– Rifampicin has excellent efficacy against stationar
y phase staphylococci– Vancomycin, teicoplanin, fusidic acid, minocycline,
trimethoprim/sulfamethoxazole, linezolid, daptomycin, tigecycline
Surgical therapy– 6 wks– 6 months (knee), 3 months (hip)
Management of Joint Prosthesis–Related Infection Caused by Staphylococcus aureus or Coagulase-NegativeStaphylococci.
~N Engl J Med 2004;350:1422-9.
Outcome
Gonococcal arthritis Staphylococcal arthritis Risk for long-term sequelae
– Symptoms > 7days before therapy– Hip joint– Gram-negative organisms
Long-term residual effects– Limited joint motion– Persistent pain…
Osteomyelitis
Osteomyelitis
One of the most difficult to teat infectious disease
Progressive destruction of bone Formation of sequestra
– Bacteria produce a local inflammatory reaction that promotes bone necrosis and the formation of sequestra
Osteomyelitis
Classification -1– Hematogenous seeding– Contiguous spread from adjacent soft tissues
and joints• Direct inoculation of microorganism into the bone
as a result of trauma or surgery
Classification -2– Acute– Chronic
Osteomyelitis
Classification -3– Cierny and Mader claissified osteomyelitis– Lee and Waldvogel classified osteomyelitis
Staging System of Osteomyelitis-1
Anatomic type– Stage 1: Medullary osteomeylitis– Stage 2: Superficial osteomeylitis– Stage 3: Localized osteomeylitis– Stage 4: Diffuse osteomeylitis
Physiologic class– A Host: Normal host– B Host
• Systemic compromise,
• Local compromise
• Systemic and local compromise
Staging System of Osteomyelitis-2Systemic or local factors that affect immune surveillance, metabolism, and local vascularity
Systemic Malnutrition Renal, hepatic failure DM Chronic hypoxia Immune disease Malignancy Extremes of age Immunosuppression
Local Chronic lymphedema Major vessel compromise Small vessel disease Vasculitis Venous stasis Extensive scarring Radiation fibrosis Neuropathy Tobacco abuse
Microbiology of Osteomyelitis
Common (>50% of class)– Staphylococcus aureus– Coagulase-negative staphy
lococci Occasionally encountered
(>25% of class) – Streptococci– Enterococci– Pseudomonas spp.– Enterobacter spp.– Proteus spp.– Escherichia coli– Serratia spp.– Anaerobes
Rarely encountered (<5% of class)
– Mycobacterium tuberculosis– Mycobacterium avium comp
lex– Dimorphic fungi– Candida spp.– Aspergillus spp.– Mycoplasma spp.– Tropheryma whipplei– Brucella spp.– Salmonella sppp.– Actinomyces
蘭陽溪口濕地
Types of Osteomyelitis, Age Distribution, Common Sites, Risk Factors
Types of Osteomyelitis
Typical Age (y)
Sites involved
Risk Factors
Hematogenous <1 Long bones and joints
Prematurity, umbilical catheter or venous cutdown, RDS, perinatal asphyxia
1-20 Long bones Infection, trauma, sickle cell disease, puncture wounds to feet
>50 Vertebrae DM, blunt trauma to spine, UTI
Contiguous >50 Femur, tibia, mandible
Hip fractures, open fractures
Clinical Features
Vague symptoms Nonspecific pain around the involved site w
ith the absence of systemic signs and symptoms
Fever Chills Local swelling Erythema
Diagnosis
Clinical grounds Radiologic, microbiologic and pathologic
tests ESR, CRP, WBC CT & MRI Causative microorganism
– Surgical sampling or needle aspiration– Swab cultures
Treatment-General Approach..1
Experimental animal models, expert opinion, respective cohort studies
S. aureus can survive in a dormant and phenotypically altered state for a long time
The optimal duration of antimicrobial therapy after surgical debridement
Treatment-General Approach..2
Goal: eradicate the infection and restore function
Medial and surgical therapy All antimicrobials should be withheld if
possible until…..…unless…. 4-6 weeks Short duration...
Treatment-General Approach..3
Antibiotic in adequate doses for a sufficient length of time
3-4 times a day Biofilm vs. Rrifampin
– Osteomyelitis – Prosthetic device-related infections
No respond – Fever, local swelling, redness, pain
~Arch Intern Med 2008;168(8):805-819
Antimicrobial Therapy of Chronic Osteomyelitis in Adults for Selected Microorganisms
OSSA– First choice
• Nafcillin or oxacillin 1.5-2g q4h IV• Cefazolin 1-2g q8h IV
– Alternative choice• Vancomycin 15mg/kg q12h IV• Nafcillin/oxacillin +rifampin 600mg qd po
Antimicrobial Therapy of Chronic Osteomyelitis in Adults for Selected Microorganisms
MRSA– First choice
• Vancomycin 15mg/kg q12h IV
– Alternative choice• Linezolid 600mg q12h PO/IV for 6 wk• Levofloxacin 500-750 mg/day PO/IV• Plus rifampin 600-900 mg/day
Antimicrobial Therapy of Chronic Osteomyelitis in Adults for Selected Microorganisms
Penicillin-sensitive streptococci– First choice
• Aqueous crystalline penicillin G 20*106 U/24 hr IV
• Ceftriaxone 1-2g q24h IV or IM • Cefazolin 1-2g q8h IV
– Alternative choice• Vancomycin 15mg/kg q12h IV
Antimicrobial Therapy of Chronic Osteomyelitis in Adults for Selected Microorganisms
Enterococci or streptococci with MIC≥ 0.5 μg/mL, Abiotrophia and Granulicatella spp.– First choice
• Aqueous crystalline penicillin G 20*106 U/24 hr IV • Ampicillin 12g/24hr IV• Plus gentamicin 1mg/kg q8h IV or IM for 1-2 wk
– Alternative choice• Vancomycin 15mg/kg q12h IV • Plus gentamicin 1mg/kg q8h IV or IM for 1-2 wk
Antimicrobial Therapy of Chronic Osteomyelitis in Adults for Selected Microorganisms
Enterobacteriaceae – First choice
• Ceftriaxone 1-2g q24h– Alternative choice
• Ciprofloxacin 500-750 mg q12h po Pseudomonas aeruginosa or Enterobacter s
pp.– First choice
• Cefepime 2g q12h IV • Meropenem 1g q8h IV
– Alternative choice• Ciprofloxacin 750 mg q12h po• Ceftazidime 2g q8h IV
Antimicrobial Drugs of Choice for Anaerobic Bacteria
J Orthop Sci (2008) 13:160–169
J Orthop Sci (2008) 13:160–169
Antimicrobial Drugs of Choice for Anaerobic Bacteria
Special Populations Sickle cell anemia
– Salmonella or S. aureus– Ceftriaxone or cefotaxime– Chloramphenicol and ciprofloxacin
IV drug abuse– Gram-negative organisms– Ceftazidime 2g q8h+AGs
Vascular insufficiency– S. aureus, Streptococcus, anaerobes, Gram–negative o
rganisms– Penicillinase-resistant penicillin+ceftazidime– Antianaerobic cephalosporin, clindamycin+ceftazidime– Ampicillin for..
Vancomycin
MRSA, ARE Marrow suppression Ototoxicity Renal toxicity Rash TDM
Linezolid
Staphylococci, streptococci, VRE Oral form, Bioavailability Bacteriostatic Pancytopenia, peripheral neuropathy High cost Experimental models: failure rate Vancomycin resistant enterococci Intolerant of vancomycin
Daptomycin
Multiple drug resistant gram positive pathogens
Well tolerated Once daily Concentration-dependent bactericidal activit
y Biofilm No need for TDM Case reports and retrospective study
Oral Antibiotic Therapy Criteria
– Confirmed osteomyelitis– Initial clinical response to parenteral antibiotic
s– Suitable oral agent available– Compliance ensured
Timing Children, Adults FQ
– Children <16-18y/o– Pregnant
Dicloxacillin, cloxacillin, cephalexin (100mg/kg/day)
Adjunctive Treatment Hyperbaric oxygen高壓氧
–提高白血球的殺菌力–直接殺死細菌、抑制細菌製造毒素–使纖維母細胞恢復活性,修補局部的組織–刺激血管新生–加成抗生素的療效
Adjunctive Treatment-Antibiotic-impregnated implant
Injury, Int. J. Care Injured (2006) 37, S95—S104
A hand-made articulating knee spacer
~J Bone Joint Surg Am. 2007;89:871-882
Antibiotic in Local Therapy
Power form Heat (70-120 )℃ Against the targeted microbial pathogen
s Vancomycin(185-188), tobramycin(168),
gentamicin(102-108), penicillin (ampicillin:199-202), erythromycin(191), colistin(200-220), cephalosporines (cefazolin:198-200), polymyxin
Local Antibiotic Therapy
Advantages – High local antibiotic concentration– Extended duration– Without exceeding systemic toxicity
Biofilm Bone cement PMMA, polymethylmethacrylate (聚甲丙烯酸甲酯 )
– Delivery vehicle– Dentistry, 1941– Orthopedic surgery, 1945– Charnley introduced PMMA bone cement to stabilize metal
hip implants , 1970– Buchholz and Engelbrecht reported the incorporation of an
tibiotics into PMMA bone cement to reduce the infection rate in arthroplasty, 1970
Septopal
Injury, Int. J. Care Injured (2006) 37, S95—S104
Preparation of Delivery Systems
Antimicrobial agents that can be used for antibiotic bead preparation (with the suggested dose in grams of powder per 40 g of PMMA cement) are as follows:– Tobramycin (3.6 g)– Vancomycin (4 g)– Cefepime (4 g)– Cefazolin (6 g)– Nafcillin (6 g)– Imipenem (4 g)
Open fractures, infected nonunions, osteomyelitis
Outcome
Acute osteomyelitis – Cure rates>80%
Chronic osteomyelitis– Dead bone and other necrotic material fro
m the infection act s a bacterial reservoir
Thank You for Your Attention!!!